- Mar. 26, 2014 - HOUNSLOW, U.K. --
In preparation of receiving our Medical Device approval for our MicroPlaSter product in Europe, we are exhibiting at ICPM5 to create broader awareness of the ground-breaking Plasma Medicine technology Adtec and Max Planck Institute have been working on.
In 2013, Phase II clinical trials of our MicroPlaSter - http://www.adtec-
en_GB/microplaster - device have been concluded after extensive testing on hundreds of patients in two German hospitals. The results are clear: for the treatment of chronic wounds, Herpes Zoster and other infections , cold plasma therapy shows significant advantages. We are extremely excited to bring this technology to a wider audience, once we have obtained a Medical Device CE mark, so more patients can benefit from more efficient and quicker healing of the above health issues, without risking negative side-effects. With increasing antibiotic resistance, alternative anti-microbial technologies are required to reduce infections.
The way this therapy works is using atmospheric, non-thermal plasma. Argon gas is used to create a plasma, operating at roughly 30 degrees Celsius, which is directed at the wound or infection. After the prescribed treatment time, the anti-bacterial qualities of this plasma cause a measurable reduction in microbial activity and thus, the wound is able to heal faster than when only traditional treatments are used. Because plasma is essentially gaseous, it can treat hard to reach areas and it is completely painless to the patient.
At our stand , we'll have our more compact model, the PlasmaTact - http://www.adtec-rf.eu/index.php/en_GB/plasmatact
, on display. Two researchers involved in the clinical trials, Dr. Georg Isbary and Dr. Tetsuji Shimizu will be available for questions. They will also be presenting a talk during the conference.
We hope to see you there!
More information about the exhibition and conference can be found on the ICPM5 website: http://icpm5.plasmabio.com/